CONTESSA-2: Tesetaxel Plus Capecitabine
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

CONTESSA-2: Tesetaxel Plus Capecitabine

Sponsor: Odonate Therapeutics, Inc.

Protocol ODO-TE-B201: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane.